Next-Generation Oncolytics Viruses: Smart, Immune-Driven Cancer Destroyers

Cancer is still one of the leading causes of death worldwide because of adverse effects and inadequate tumor clearance. Oncolytic Viruses (OVs) offer a new and promising approach by selectively infecting and destroying cancer cells while protecting healthy tissue. By both directly lysing tumors and strengthening the immune system, these viruses improve anticancer responses in ways that conventional medicines are unable to. This paper aims to provide a comprehensive overview of next-generation oncolytic virotherapy with a focus on their underlying mechanisms, therapeutic potential, and clinical developments. By merging data from preclinical and clinical studies, this review aims to establish how OVs are becoming a crucial part of cancer immunotherapy while recognizing that challenges remain. For methodology, a comprehensive review of recent research, including lab tests and clinical trials, was conducted. Among the numerous DNA and RNA viruses we studied were adenovirus, herpesvirus, reovirus, poliovirus, measles virus, coxsackievirus, and other naturally occurring and genetically modified viruses. The review's primary subjects included tumor selectivity, immune activation potential, genetic changes, delivery strategies, and safety and efficacy findings from human trials. The results demonstrate that OVs effectively target tumor cells by altering the tumor microenvironment and exploiting their unique limitations. Genetically modified viruses that produce cytokines like GM-CSF and IL-12 enhance immune responses. Clinical trials are advancing an abundance of alternatives, and clinically approved drugs such as talimogene laherparepvec (T-VEC) have demonstrated significant benefits. Immune suppression and targeting limitations may be resolved by immune checkpoint inhibitor combined therapies and novel delivery methods. In conclusion, oncolytic virotherapy is a highly advanced and innovative method of treating cancer. Ongoing research is necessary to improve virus delivery, increase therapeutic efficacy, and increase availability-all of which have the potential to significantly change cancer care worldwide.